EP3969015A1 - Lichthärtende zusammensetzungen zur behandlung der onychomykose (nagelpilz) - Google Patents
Lichthärtende zusammensetzungen zur behandlung der onychomykose (nagelpilz)Info
- Publication number
- EP3969015A1 EP3969015A1 EP20731957.5A EP20731957A EP3969015A1 EP 3969015 A1 EP3969015 A1 EP 3969015A1 EP 20731957 A EP20731957 A EP 20731957A EP 3969015 A1 EP3969015 A1 EP 3969015A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- light
- onychomycosis
- nail
- dimethacrylate
- methacrylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 208000010195 Onychomycosis Diseases 0.000 title claims abstract description 28
- 201000005882 tinea unguium Diseases 0.000 title claims abstract description 24
- 206010034016 Paronychia Diseases 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 claims abstract description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 4
- 239000007858 starting material Substances 0.000 claims description 20
- 239000000945 filler Substances 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 206010061217 Infestation Diseases 0.000 claims description 13
- 239000000049 pigment Substances 0.000 claims description 13
- MKVYSRNJLWTVIK-UHFFFAOYSA-N ethyl carbamate;2-methylprop-2-enoic acid Chemical compound CCOC(N)=O.CC(=C)C(O)=O.CC(=C)C(O)=O MKVYSRNJLWTVIK-UHFFFAOYSA-N 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 claims description 10
- 229930185605 Bisphenol Natural products 0.000 claims description 10
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 10
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 claims description 10
- 229930006711 bornane-2,3-dione Natural products 0.000 claims description 10
- 239000002966 varnish Substances 0.000 claims description 10
- KPKMKACZPZUNDP-UHFFFAOYSA-N 2-methylprop-2-enoic acid;phosphoric acid Chemical compound OP(O)(O)=O.CC(=C)C(O)=O.CC(=C)C(O)=O KPKMKACZPZUNDP-UHFFFAOYSA-N 0.000 claims description 7
- ZMJOQTILTVQJJE-UHFFFAOYSA-N ethenol;2-methylprop-2-enoic acid Chemical compound OC=C.CC(=C)C(O)=O ZMJOQTILTVQJJE-UHFFFAOYSA-N 0.000 claims description 7
- HWSSEYVMGDIFMH-UHFFFAOYSA-N 2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOC(=O)C(C)=C HWSSEYVMGDIFMH-UHFFFAOYSA-N 0.000 claims description 4
- FZUGPQWGEGAKET-UHFFFAOYSA-N parbenate Chemical group CCOC(=O)C1=CC=C(N(C)C)C=C1 FZUGPQWGEGAKET-UHFFFAOYSA-N 0.000 claims description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 2
- AMFGWXWBFGVCKG-UHFFFAOYSA-N Panavia opaque Chemical compound C1=CC(OCC(O)COC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCC(O)COC(=O)C(C)=C)C=C1 AMFGWXWBFGVCKG-UHFFFAOYSA-N 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- QUZSUMLPWDHKCJ-UHFFFAOYSA-N bisphenol A dimethacrylate Chemical compound C1=CC(OC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OC(=O)C(C)=C)C=C1 QUZSUMLPWDHKCJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 claims description 2
- 229920005906 polyester polyol Polymers 0.000 claims description 2
- 210000000282 nail Anatomy 0.000 abstract description 34
- 230000001857 anti-mycotic effect Effects 0.000 abstract description 8
- 239000002543 antimycotic Substances 0.000 abstract description 8
- 210000004906 toe nail Anatomy 0.000 abstract description 4
- 239000004922 lacquer Substances 0.000 abstract description 3
- 210000004905 finger nail Anatomy 0.000 abstract description 2
- 206010061304 Nail infection Diseases 0.000 abstract 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000000078 claw Anatomy 0.000 abstract 1
- 238000006116 polymerization reaction Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910052788 barium Inorganic materials 0.000 description 6
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 239000003505 polymerization initiator Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UEKHZPDUBLCUHN-UHFFFAOYSA-N 2-[[3,5,5-trimethyl-6-[2-(2-methylprop-2-enoyloxy)ethoxycarbonylamino]hexyl]carbamoyloxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC(=O)NCCC(C)CC(C)(C)CNC(=O)OCCOC(=O)C(C)=C UEKHZPDUBLCUHN-UHFFFAOYSA-N 0.000 description 2
- SJEBAWHUJDUKQK-UHFFFAOYSA-N 2-ethylanthraquinone Chemical compound C1=CC=C2C(=O)C3=CC(CC)=CC=C3C(=O)C2=C1 SJEBAWHUJDUKQK-UHFFFAOYSA-N 0.000 description 2
- NPKSPKHJBVJUKB-UHFFFAOYSA-N N-phenylglycine Chemical compound OC(=O)CNC1=CC=CC=C1 NPKSPKHJBVJUKB-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000002318 adhesion promoter Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- GYVGXEWAOAAJEU-UHFFFAOYSA-N n,n,4-trimethylaniline Chemical compound CN(C)C1=CC=C(C)C=C1 GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 229940126573 antibacterial therapeutic Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/01—Orthopaedic devices, e.g. splints, casts or braces
- A61F5/11—Devices for correcting deformities of the nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
- C08F2/50—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light with sensitising agents
Definitions
- the present invention relates to compositions for treating
- Onychomycosis which is without a classic antifungal agent
- Onychomycosis (nail fungus) is not a serious but common condition. According to surveys, 5-12% of Europeans have dermatophytes in their nails; the incidence increases with age.
- the classic treatment consists in the simple case of an antifungal cream or an antifungal nail polish.
- the nail polish contains an antifungal agent such as Bifonazole, clotrimazole, ciclopirox or amorolfine.
- Surgical removal of the nail may be necessary in the case of severe illnesses, and there is often a need for systemic administration of oral antimycotics such as Griseofulvin, itraconazole, terbinafine or fluconazole, which in turn have risks and side effects.
- WO 2018/207164 A1 describes a kit for correcting malgrown toenails or fingernails, by means of which a photopolymerizable substance is applied to the nail in order to correct it mechanically.
- the document also mentions an optional embodiment with an addition of antimycotics in order to also carry out an antimycotic therapy at the same time as the mechanical correction.
- the present invention relates to the use of a photopolymerizable composition based on acrylate for the production of a light-curing varnish for the therapy of onychomycosis or bacterial nail infestation.
- Photopolymerizable compositions according to the invention based on acrylate for the production of a light-curing varnish for the therapy of onychomycosis or bacterial nail infestation contain, in particular, aliphatic urethane dimethacrylate, hydroxyethylene methacrylate, phosphate dimethacrylate, triethylene glycol dimethacrylate, Bisphenyl glycidyl dimethacrylate, triethylene glycol dimethacrylate, alkoxylated bisphenol A dimethacrylate, isopropylidenediphenyl bisoxyhydroxypropyl methacrylate, 2-hydroxyethyl methacrylate, polyester polyol tetraacrylate, or mixtures of the above components in combination with a starter.
- the present invention relates to the use of a
- the material for the light-curing lacquer contains in particular fillers and pigments as additives.
- the particulate additives have a diameter in the range of 0.1-10 ⁇ m, preferably they are smaller than 5 ⁇ m.
- the fillers based on barium glass make a significant contribution to the mechanical properties of the light-curing paint.
- pigments can also be contained in the composition in order to give the lacquer formed an aesthetic appearance. The pigments, too, should preferably have a diameter in the range from 0.1-10 ⁇ m.
- compositions are:
- Solvents e.g. Ethanol, propanol, ethyl acetate,
- film formers such as DI-HEMA trimethylhexyl dicarbamate
- antioxidants such as butylhydroxytoluene (BHT), butylhydroxyanisole (BHA) or pentaerythryl tetra-di-t-butylhydroxycinnamate,
- compositions according to the invention also contain polymerization starters which can trigger the desired polymerization reaction by irradiation with light.
- polymerization starters which can trigger the desired polymerization reaction by irradiation with light.
- all classic polymerization starters are suitable for this purpose suitable.
- the combination of camphorquinone with amino starters, namely tertiary amines (e.g. triethanolamine, N, N-dimethyl-p-toluidine, triethylamine, ethyl 4-dimethylaminobenzoate, N, N-tetramethylaniline) has proven particularly suitable.
- 2-ethyl-anthraquinone can be used in combination with N-phenyl glycine or acylphosphine.
- compositions described in WO 2018/207164 A1 are particularly suitable for the therapy of onychomycosis, even if the compositions do not contain an antimycotic.
- the kit for nail correction described in WO 2018/207164 A1 contains a) containing a primer
- Component a of the kit according to the invention is a primer that acts as an adhesion promoter in the application described in WO 2018/207164 A1. In the course of the investigations into the present invention it has been found that the primer is most likely responsible for the antifungal effect of the composition.
- the adhesion promoter contains 40-60% hydroxyethylene methacrylate and 40-60% phosphate dimethacrylate as well as 0.1-1.0% polymerization initiator.
- Polymerization initiators are described in more detail below.
- the mixing ratio can vary within the scope of the percentages given above.
- Advantageously the two methacrylates are contained in approximately the same ratio. It goes without saying that all components add up to 100%.
- the nail brace further described in WO 2018/207164 A1 is formed by means of the photopolymerizable material b. It is a composition containing
- composition range allows a different setting of the mechanical properties, in the form of different degrees of hardness.
- it has proven useful to provide two compositions, one of which is comparatively soft and the other is comparatively hard.
- the soft composition includes, for example
- the hard composition contains, for example
- the monomers bisphenol (A) - (di) methacrylate and urethane dimethacrylate contained in the compositions are preferably contained in approximately the same amount.
- Mixing ratios in which the two main components are contained in a mass ratio between 1: 5 and 5: 1 are generally suitable. Especially Mixing ratios in which the two main components are contained in a mass ratio between 1: 2 and 2: 1 are preferred.
- the material for the light-curing nail brace also contains fillers and
- Pigments These are fillers based on silicate (silica filler), based on ground barium glass (barium glass filler) and polymer particles.
- the particulate additives have a diameter in the range of 0.1-10 ⁇ m, preferably they are smaller than 5 ⁇ m.
- the fillers based on barium glass contribute significantly to the mechanical properties of the nail braces.
- the composition can also contain pigments in order to give the nail brace formed an aesthetic appearance.
- the pigments too, should preferably have a diameter in the range from 0.1-10 ⁇ m.
- compositions are:
- Solvents e.g. Ethanol, propanol, ethyl acetate,
- film formers such as DI-HEMA trimethylhexyl dicarbamate
- antioxidants such as butylhydroxytoluene (BHT), butylhydroxyanisole (BHA) or pentaerythryl tetra-di-t-butylhydroxycinnamate,
- the material of the light-curing nail brace according to WO 2018/207164 A1 seems to contribute to the success of therapy in onychomycosis, but is not essential. Therapy of onychomycosis by applying the material of the light-curing nail brace alone seems to be possible
- compositions according to the invention also contain polymerization starters which can trigger the desired polymerization reaction by irradiation with light.
- polymerization starters which can trigger the desired polymerization reaction by irradiation with light.
- all classic polymerization initiators are suitable for this.
- the combination of camphorquinone with amino starters, namely tertiary amines (e.g. triethanolamine, N, N-dimethyl-p-toluidine, triethylamine, ethyl 4-dimethylaminobenzoate, N, N-tetramethylaniline) has proven particularly suitable.
- 2-ethyl-anthraquinone can be used in combination with N-phenyl glycine or acylphosphine.
- the present invention therefore particularly relates to the use of a
- the present invention further relates to the use of a composition containing
- the finished composition can surprisingly be stored for a long time without a
- Polymerization reaction occurs.
- the polymerization reaction only occurs after lighting with an adapted light source.
- an LED light source with a wavelength of approx. 425 nm and a light output of 1000-1500mW / cm 2 can be used.
- the invention can be used in the context of a nail correction treatment, as in
- WO 2018/207164 A1 described can be used.
- any onxychomycosis that may be present is treated in parallel.
- the kit according to the invention can also be used without nail correction treatment.
- the primer is first applied over the entire area of the affected nail. It is particularly important to ensure that the nail is dry.
- the affected nail should not have been in contact with water any longer, especially in the 24 hours prior to application.
- the patient should for example not having bathed.
- a short wash or shower is harmless provided the nail has been dried well again.
- the nail can be dried with a heat gun.
- the polymerization is started by means of a light source (preferably blue light with approx. 425 nm and at least 1000 mW / cm 2 ).
- the polymerization When using a conventional light source, the polymerization is completed after a period of 5 seconds to 60 seconds; as a rule, a 10-second exposure is sufficient. The light-curing nail brace is then applied. In the case of a purely antimycotic treatment, the application can take place over a large area. If a mechanical correction is to be made at the same time, the application takes place as described in WO 2018/207164 A1.
- the polymerization is preferably started immediately by illuminating with the above-mentioned light source. It is important to keep the nail in the desired shape. This step is also usually completed after a period of 5 to 60 seconds. The material can then be sanded again so that there are no edges on which tissue (e.g. stockings) could get stuck.
- the use of the primer is sufficient for the therapy of onychomycosis in many cases.
- compositions of the invention are preferably used in
- vials made of glass or plastic with an application brush or an application brush are suitable for the primer.
- the compositions for the manufacture of light-curing nail braces are typically more viscous and are preferably in cartridges for use with a cartridge gun
- All containers are preferably opaque.
- compositions according to the invention With the necessary material is made available to treat onychomycoses effectively without having to use classic antimycotics locally or systemically. It has surprisingly been found that the compositions described are also suitable for treating bacterial infections of the nails (e.g. by Staphylocccus aureaus
- compositions are applied to the affected nail as described above for onychomycosis.
- compositions according to the invention can optionally also contain antimycotic and / or antibacterial therapeutics, such as piroctone olamine.
- Figure 1 shows a human toenail before therapy.
- Figure 2 shows the same toenail after therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Polymers & Plastics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nursing (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019003486.4A DE102019003486B4 (de) | 2019-05-17 | 2019-05-17 | Zusammensetzungen zur Behandlung der Onychomykose |
DE102019008797 | 2019-12-18 | ||
PCT/IB2020/054610 WO2020234712A1 (de) | 2019-05-17 | 2020-05-15 | Lichthärtende zusammensetzungen zur behandlung der onychomykose (nagelpilz) |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3969015A1 true EP3969015A1 (de) | 2022-03-23 |
Family
ID=71078546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20731957.5A Pending EP3969015A1 (de) | 2019-05-17 | 2020-05-15 | Lichthärtende zusammensetzungen zur behandlung der onychomykose (nagelpilz) |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220226365A1 (de) |
EP (1) | EP3969015A1 (de) |
CA (1) | CA3140967A1 (de) |
WO (1) | WO2020234712A1 (de) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008041049A1 (de) * | 2008-08-06 | 2010-02-11 | Sonja Spohler | Verwendung einer antimykotischen Zusammensetzung zur topischen Behandlung von Pilzerkrankungen von Fuß- und Fingernägeln |
DE102017004546B4 (de) | 2017-05-12 | 2022-01-05 | L/N Health And Beauty Aps | Kit zur Nagelkorrektur |
-
2020
- 2020-05-15 US US17/611,999 patent/US20220226365A1/en active Pending
- 2020-05-15 WO PCT/IB2020/054610 patent/WO2020234712A1/de active Application Filing
- 2020-05-15 CA CA3140967A patent/CA3140967A1/en active Pending
- 2020-05-15 EP EP20731957.5A patent/EP3969015A1/de active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020234712A1 (de) | 2020-11-26 |
US20220226365A1 (en) | 2022-07-21 |
CA3140967A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0913154B1 (de) | Antipsoriatisch wirksamer Nagellack | |
EP1267932B1 (de) | Antiinfektive wirkstoffkombinationen und ihre verwendung zur topischen behandlung von pilzerkrankungen der fuss- und fingernägel | |
WO2012163851A2 (de) | Leicht ablösbare nagellack-zusammensetzung | |
EP3585324B1 (de) | Kit zur nagelkorrektur | |
WO1982001128A1 (en) | Composition used for dental cosmetics | |
DE4108664C2 (de) | Nagellack und Verwendung desselben | |
EP2482766B1 (de) | Korrekturverfahren für hand- oder fussnägel | |
DE102011014149A1 (de) | Lichthärtender Nagellack | |
EP0100458A2 (de) | Mittel zur Behandlung von Wunden | |
EP3969015A1 (de) | Lichthärtende zusammensetzungen zur behandlung der onychomykose (nagelpilz) | |
DE102019003486B4 (de) | Zusammensetzungen zur Behandlung der Onychomykose | |
CH648481A5 (de) | Nagelschutzpraeparat zur festigung und/oder haertung lebender finger- und/oder zehennaegel. | |
EP2136765B1 (de) | Kit zum befestigen eines dentalen restaurationsmaterials an einer zahnsubstanz | |
DE102013101035A1 (de) | Leicht ablösbare Nagellack-Zusammensetzung | |
DE102012019194A1 (de) | Medizinisches Präparat umfassend einen Träger mit Polyhexanid oder Octenidin | |
EP1245219B1 (de) | Aushärtbare Dentalzusammensetzung sowie Dentalsystem | |
DE60224049T2 (de) | Pastenartige polymerisierbare Zusammensetzung | |
DE102008041049A1 (de) | Verwendung einer antimykotischen Zusammensetzung zur topischen Behandlung von Pilzerkrankungen von Fuß- und Fingernägeln | |
EP3221005A1 (de) | Mittel und verfahren zur temporären verformung keratinhaltiger fasern | |
DE3340991A1 (de) | Verwendung von dimethylether als treib- und loesungsmittel | |
DE4437140A1 (de) | Kunstnagel zur Behandlung von Pilzerkrankungen der Nägel des Menschen | |
DE202005021127U1 (de) | Nagellack Zusammensetzung für Kipp- und Ultraweißeffekt | |
DE102014108727A1 (de) | Beschichtete Erzeugnisse für den oralen Bereich, Verwendung und Beschichtungsverfahren für Chitosan | |
DE10256690A1 (de) | Dentales Restaurationsmaterial |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220131 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231004 |